title: Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
abstract: Radium-223 dichloride (radium-223) is an important therapeutic option for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no visceral disease. The unique mechanism of action of this first-in-class alpha-emitting radiopharmaceutical underlies its favorable safety profile and low incidence of myelosuppression. In the pivotal phase 3 ALpharadin in SYMptomatic Prostate CAncer Patients study, radium-223 reduced the risk of death by 30% and prolonged time to first symptomatic skeletal event by 5.8 months. This article summarizes current guidelines and clinical studies that led to the approval of radium-223 as an overall survival therapy, and discusses the urologist's perspective on using radium-223 in clinical practice.
authors: Department of Urology, Carolina Urologic Research Center, Myrtle Beach, SC. Electronic address: nshore@gsuro.com.
authors: Neal D
authors: ND
authors: Shore
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D010353:Patient Education as Topic; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology; D011868:Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D011883:Radium / Q000009:adverse effects / Q000627:therapeutic use*; D014572:Urology
chemical_list: D000970:Antineoplastic Agents; D011868:Radioisotopes; C581106:radium Ra 223 dichloride; D011883:Radium